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Hereditary breast and ovarian cancer (HBOC) is an inherited cancer
syndrome that is associated with mutations in the BRCA1 and BRCA2 genes.
Carriers of BRCA mutations, both men and women, are at an increased risk for
developing certain cancers. Carriers are most notably at an increased risk to
develop breast and ovarian cancers; however an increased risk for prostate cancer,
melanoma, and pancreatic cancers has also been associated with these mutations. In
2009 the American Congress of Obstetricians and Gynecologists (ACOG) released a
practice bulletin stating that evaluating a patient’s risk for HBOC should be a
routine part of obstetric and gynecologic practice.
iv

A survey was created and completed by 83 obstetricians and gynecologists in
the greater Houston, TX area. The survey consisted of four sections designed to
capture demographic information, attitudes towards HBOC and BRCA testing,
utilization of BRCA testing, and the overall knowledge of respondents with regards
to HBOC and BRCA testing. This study found that the majority of participants
indicated that they felt that obstetricians and gynecologists should have the
primary responsibility of identifying patients who may be at increased risk of
carrying a BRCA mutation. Moreover, this study found that the majority of
participants indicated that they felt comfortable or very comfortable in identifying
patients at an increased risk of carrying a BRCA mutation. However, only about a
quarter of participants indicated that they order BRCA genetic testing one to two
times per month or more. Lastly, this study demonstrates that the overall
knowledge of HBOC and BRCA testing among this population of obstetricians and
gynecologists is poor.
The results of this study stress the need for more education regarding HBOC,
genetic testing, and strategies for identifying patients that may be at risk for having
a mutation in a BRCA gene. Furthermore, it reiterates the importance of raising
awareness to current practice guidelines and recommendations that can assist
obstetricians and gynecologist to better identify and manage patients that may be at
an increased risk of having HBOC.
v
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BACKGROUND
Introduction
Hereditary breast and ovarian cancer (HBOC) is an inherited cancer syndrome
that is associated with mutations in the BRCA1 and BRCA2 genes [1,2]. Mutations in
either BRCA1 or BRCA2 are inherited in an autosomal dominant manner, and these
mutations cause carriers, both men and women, to be at an increased risk for
developing certain cancers. Carriers are most notably at an increased risk to
develop breast and ovarian cancers; however an increased risk for prostate cancer,
melanoma, and pancreatic cancers have also been associated with these mutations
[3,4].

Prevalence
Originally, it was estimated that 1/5000-1/10000 individuals in the general
population carried a mutation in either the BRCA1 or BRCA2 gene [5]. However,
with recent advancements in research and testing, the accepted prevalence of BRCA
mutation carriers is now thought to be between to 1/400 and 1/800 individuals in
the general population [6,7]. This number becomes even more significant in select
populations, such as Ashkenazi Jewish individuals, where founder mutations in
BRCA1 and BRCA2 have been identified. Three specific mutations have been
identified in the Ashkenazi Jewish population and include the 185delAG and
1

5382insC mutations in the BRCA1 gene and the 6174delT mutation in the BRCA2
gene [8]. The prevalence of a BRCA mutation in the Ashkenazi Jewish population is
1/40 [9]. Other specific founder mutations have been described in individuals from
Iceland, Norway, Finland, Sweden, France, the Netherlands, Italy, Mexico, and
Pakistan [10].
BRCA1
The BRCA1 gene, located on chromosome 17q21, was first mapped in 1990
[11,12]. The BRCA1 gene consists of 22 coding exons, spanning 80 kb of DNA [13].
Since that time it was thought to have many regulatory functions within the cell.
One such function of the BRCA1 gene is to act as a negative regulator of tumor
growth or as a tumor suppressor gene [1]. Moreover, the BRCA1 gene is thought to
play a part in the repair and regulation of cell-cycle checkpoints in response to
DNA lesions with indications of damage [14]. The exact molecular mechanisms and
role of the BRCA1 gene are still under investigation today. To date, there have been
more than 1600 mutations identified in the BRCA1 gene, the majority of which are
frameshift mutations resulting in non-functional protein products [15].

BRCA2
The BRCA2 gene, located on chromosome 13q12-q13, was identified shortly
after the BRCA1 gene in 1994 [2]. This gene consists of 26 coding exons and spans 70
2

kb of DNA [13]. Like BRCA1, the BRCA2 gene is a tumor suppressor gene and its
primary role is to maintain genomic integrity in DNA. Studies have indicated that
cells with a non-functional BRCA2 gene have been shown to be hypersensitive to
ionizing radiation resulting in permanent DNA damage [16,17]. To date, there have
been approximately 1800 mutations identified in the BRCA2 gene, which include
frameshift deletions, insertions, and nonsense mutations [15]. As both BRCA genes
act as tumor suppressor genes, individuals identified with a mutation in either their
BRCA1 or BRCA2 gene are at an increased risk to develop breast, ovarian, and other
associated cancers.

Breast and Ovarian Cancer Risk
In the general population, a woman has an approximate 12% risk of
developing breast cancer and a 1.4% risk of developing ovarian cancer during her
lifetime [18]. These risk estimates greatly increase if a mutation in either the BRCA1
or BRCA2 genes is identified. Hereditary forms of both breast and ovarian cancer
make up about 5-10% of all breast and ovarian cancers seen in the population [19].
Both the BRCA1 and BRCA2 genes have variable penetrance. That is to say, a
mutation in BRCA1 or BRCA2 will significantly increase the likelihood to
developing breast and ovarian cancer; however, all carriers do not develop cancer
during their lifetime. Differences in penetrance can be seen between individuals
3

with BRCA1 or BRCA2 mutations and even between family members who carry the
same identified mutation [20,21]. While generally referenced as a pair, both the
BRCA1 and BRCA2 genes carry their own risk estimates with regards to developing
breast and ovarian cancer. Several studies have examined the risk for developing
breast and ovarian cancer in both the BRCA1 and BRCA2 genes individually. In
2003, a meta-analysis of 22 studies looking at over 8,000 index cases found that
individuals that carried a BRCA1 mutation had a 65% risk of developing breast
cancer and a 39% risk of developing ovarian cancer by the age of 70 [22]. Analysis of
this same study population also indicated that individuals that carried a BRCA2
mutation had a 45% risk of developing breast cancer and an 11% risk of developing
ovarian cancer before the age of seventy [22]. Following this analysis, in 2006, a
separate group again tried to quantify the breast and ovarian cancer risks associated
with BRCA1 and BRCA2 through population based studies. The first study looked
at risks before the age of 80 years and found that individuals that carried a BRCA1
mutation had a 90% risk of developing breast cancer and 24% risk of developing
ovarian cancer [7]. The same group found that individuals with a mutation in the
BRCA2 gene had a 41% risk to develop breast cancer and an 8.4% risk for
developing ovarian cancer [7]. These two studies represent the variability seen in
the literature with regards to associated risk. Based on the most up to date
surveillance epidemiology and end results (SEER) cancer statistics, women that
4

carry a BRCA1 or BRCA2 mutation have a 60% lifetime risk to develop breast cancer
and a 15-40% risk to develop ovarian cancer [18].
Other studies have looked particularly at the risk to develop a second
primary breast cancer in the same (ipsilateral) or opposite breast (contralateral).
Most studies have found that younger age at the primary diagnosis is strongly
correlated to increased risk for developing a contralateral breast cancer [23]. A
woman without a BRCA mutation has a lifetime risk of 10% to develop
contralateral breast cancer. For individuals with a mutation in either the BRCA1 or
the BRCA2 gene this risk is increased to 13-30% [24,25]. One population based
study, looking at women with a breast cancer detected before the age of 55 years,
found that individuals with a BRCA1 mutation had a 4.5 fold increased risk while
those that carried a mutation in the BRCA2 gene had a 3.4 fold increased risk for
developing contralateral breast cancer [24]. In 2011, a UK cancer research team
confirmed these results. They found that age of the primary breast cancer did in
fact influence the risk estimates for developing contralateral breast cancer.
Moreover, they quantified their findings showing that individuals with a BRCA1
mutation had an approximate 36% risk estimate for developing contralateral breast
cancer within 15 years from the primary diagnosis. Those with BRCA2 mutations
were found to have 28.5% risk estimate for the same period [26]. Studies have
shown however, that the risk for recurrence of breast cancer after surgery in
5

known BRCA carriers is not at an increased risk as compared to the general
population [27]. Risk assessments for breast (both ipsilateral and contralateral) and
ovarian cancers are constantly being investigated and updated, as more is
understood.

Other Associated Cancers
The association between mutations in the BRCA genes and breast and
ovarian cancer has been well established in the literature over the past twenty
years. However, breast and ovarian cancers are not the only cancers associated with
the BRCA1 and BRCA2 genes. Fallopian tube carcinoma, rare in the general
population, has been associated with both BRCA1 and BRCA2 mutations [18,28,29].
For individuals with a known BRCA mutation the risk for fallopian tube carcinoma
increases to 0.6%, about 120-fold increase compared to the general population [30].
Studies have also found up to an 11% lifetime risk for BRCA carriers to develop
primary papillary serous carcinoma of the peritoneum, as compared to the general
population risk of 0.07-0.24%.
Individuals with BRCA2 mutations also have an increased risk of developing
pancreatic cancer, male breast cancer, and prostate cancer. While the general
population risk of male breast cancer is less than 1%, the National Cancer Institute
(NCI) evaluated 97 males with breast cancer and found that those with a BRCA2
6

mutation had a 6.8% risk to develop breast cancer and men with a BRCA1 mutation
had a 1.2% risk for breast cancer [32,33]. In the general population a man has about
a 16% chance of developing prostate cancer in his lifetime [34]. Men with BRCA2
mutations have a 4.6 fold risk over the general population of developing prostate
cancer [4]. Similarly, there is a slightly increased 1.07 fold risk for individuals with a
BRCA1 mutation to develop prostate cancer before the age of 70 years [35]. BRCA2
mutations have also been shown to increase the risk for pancreatic cancer. One
study found that individuals with a BRCA2 mutation have a 7.3% risk to develop
pancreatic cancer in comparison to the 1.45% lifetime risk in the general population
[18,36].
Other cancers such as gallbladder, bile duct, and melanoma have also been
associated with BRCA2 mutations [4]. In the general population the lifetime risks
for developing both gallbladder and bile duct cancers are less than one percent
while the lifetime risk to develop melanoma is 2% [18]. For BRCA2 mutation
carriers the relative risk of developing gallbladder and bile duct cancers becomes
4.97, while the relative risk for developing melanoma is 2.58 [4]. Identifying
individuals that carry mutations in BRCA1 and BRCA2 is clinically important in
order to provide accurate cancer risk assessment and in order to create personalized
management plans.

7

Molecular Testing
Testing for mutations in BRCA1 and BRCA2 became commercially available
in the United States in 1996 through Myriad Genetics laboratory. While Myriad
Genetics is currently the only laboratory offering full sequencing of the BRCA
genes, other laboratories are offering both multisite and single site testing. Through
Myriad, there are currently four testing types offered with regards to the BRCA
genes [37]. These four mutational analyses are comprehensive analysis, single site
analysis, multisite analysis, and rearrangement analysis. Comprehensive
BRACAnalysis®, includes full sequencing of the BRCA1 and BRCA2 genes as well
as analysis of five specific large rearrangements in the BRCA1 gene. BRCA1 full
sequencing includes both forward and reverse directions of 22 coding exons and
about 750 base pairs in the adjacent non-coding introns. Similarly, BRCA2 full
sequencing includes both forward and reverse directions of 26 coding exons and
approximately 900 base pairs in the adjacent non-coding introns. The five specific
large rearrangements of BRCA1 included in comprehensive BRACAnalysis®
include founder mutations found in individuals of Dutch and European ancestry
[38]. Single site BRACAnalysis® is for individuals where a known familial
deleterious mutation has been identified. This testing type evaluates an individual
for a specific mutation that has previously been identified in their family. Multisite
BRACAnalysis® is designed to look for the three founder mutations that have been
8

identified in the Ashkenazi Jewish population. Ashkenazi Jewish individuals have
been found to have a 1/40 risk to be a carrier of a BRCA mutation [39]. One study
evaluating a group of unselected Ashkenazi Jewish patients with breast cancer
found that 12% had a mutation in one of these three founder mutation sites [40].
Similarly another study identified that 35% of unselected Ashkenazi Jewish patients
with ovarian cancer carried one of the three founder mutations [41]. If a woman of
Ashkenazi Jewish decent were to carry a BRCA mutation, 90% of the time it would
be one of these three founder mutations. Therefore, recommendations for multisite
testing for individuals of Ashkenazi Jewish ancestry regardless of a known familial
mutation is indicated because of the high incidence in this population. Finally,
BRACAnalysis® Rearrangement testing (BART) evaluates all coding exons of both
the BRCA1 and BRCA2 genes for deletions and duplications [37]. Less than 2% of
individuals with a strong family history suggestive of carrying a BRCA mutation
with no deleterious mutation identified via comprehensive testing will have a
positive BART testing result [42]. While BART testing is typically not covered by
most insurance plans, utilization of this testing may be beneficial in individuals
with previously negative comprehensive BRACAnalysis®. For patients evaluated
for having a high risk of BRCA mutation and ROA October 2011

Testing Results
9

There are three types of BRCA test results: positive, negative, and variant of
uncertain significance (VUS). Individuals undergoing comprehensive
BRACAnalysis® may receive one of the three aforementioned results. A negative
test would indicate that no mutation was present or that a known non-deleterious
change, which is found in the general population, was present and classified as a
“favor polymorphism”. A positive test result indicates a mutation was found and
may be classified as a deleterious mutation or suspected deleterious depending on
the level of clinical certainty backed by literature. This would indicate that the
patient would benefit from added screening. Finally a VUS would indicate that a
mutation was found but the exact nature of the mutation (deleterious or not) is still
not known at this time. A VUS will continue to be studied by Myriad in an attempt
to reclassify it as deleterious or a favor polymorphism. For single site
BRACAnalysis®, multisite BRACAnalysis®, and BRACAnalysis® Rearrangement
testing (BART) the possible results are either negative or positive.

Identifying at risk individuals
Many professional guidelines have been implemented in regards to
identifying individuals who may be at increased risk of having a mutation in either
BRCA1 or BRCA2 gene. The American Congress of Medical Genetics (1999), The
American Society of Clinical Oncology (2003), The American Congress of Obstetrics
10

and Gynecology (2009), and the United States Preventive Services Task Force (2005)
have all published guidelines regarding the identification of patients at a high risk
to carry at BRCA mutation. The National Comprehensive Cancer Network
developed a set of clinical practice guidelines for identifying individuals at
increased risks to have a mutation in either of the BRCA genes [57]. Those
individuals identified may benefit from genetic testing and increased surveillance.
Criteria for further risk evaluation, according to the NCCN guidelines, include
individuals with one or more of the following:
For those individuals with cancer:
1. Early onset of breast cancer (Clinically using age <50 years
old)
2. Triple negative breast cancer (estrogen receptor negative,
progesterone receptor negative, and Human Epidermal
Growth Factor Receptor 2 negative)
3. Two breast cancer primaries in an individual
4. Breast cancer at any age, with
i.

1 close relative with breast cancer ≤ 50 years old

ii.

1 close relative with epithelial ovarian/fallopian
tube/primary peritoneal cancer at any age

iii.

2 close relatives with breast cancer and/or
11

pancreatic cancer
5. A combination of breast cancer with one or more of the
following: thyroid cancer, sarcoma, adrenocortical carcinoma,
endometrial cancer, pancreatic cancer, brain tumors, diffuse
gastric cancer, dermatologic manifestations, or
leukemia/lymphoma on the same side of family
6.

Ovarian/fallopian tube/primary peritoneal cancer

7.

Male breast cancer

Unaffected individuals, with a family history of one or more of the
following:
1.

≥ 2 breast primaries from the same side of family (maternal or
paternal)

2.

≥ 1 ovarian primary from the same side of family (maternal
or paternal)

3.

A combination of breast cancer with one or more of the
following: thyroid cancer, sarcoma, adrenocortical carcinoma,
endometrial cancer, pancreatic cancer, brain tumors, diffuse
gastric cancer, dermatologic manifestations, or
leukemia/lymphoma on the same side of family

4.

A known mutation in a breast cancer susceptibility gene
12

5.

From a population at risk (Ex. Ashkenazi Jewish ancestry)

6.

Male breast cancer [57]

Following the clinical availability of testing the U.S. Preventive Services Task Force
(USPSTF) released a statement recommending that “women whose family history is
associated with an increased risk for deleterious mutations in BRCA1 or BRCA2
genes be referred for genetic counseling and evaluation for BRCA testing” [58].

Screening and Management
Ordering BRCA testing and accurately interpreting the results is an
important aspect to assist in formulating appropriate screening, risk reduction
options, and medical management plans. Clinical management recommendations
have been published, by the National Comprehensive Cancer Network (NCCN), for
individuals identified with a mutation in either of the BRCA genes. These
recommendations include both increased and more frequent screening as well as
prophylactic surgical options. The NCCN breast guidelines indicate monthly self
breast examination beginning at 18 years old, semiannual clinical breast
examinations beginning by age 25 years and annual mammograms and breast MRI
screening at age 25 years or 10 years before the earliest age of onset in the
individuals family [43,44]. Surgical options such as prophylactic bilateral
mastectomy in individuals with BRCA mutations has been shown to reduce breast
13

cancer risk by up to 90% [45,46]. While screening guidelines for breast cancer risks
have been established, ovarian cancer screening has been shown to be ineffective
[47]. Transvaginal ultrasound and CA-125 levels every six months starting at 35
years old or 5-10 years before the earliest age of onset in the individuals family is
still the recommendation despite its lack of clinical utility [48]. Prophylactic bilateral
salpingho-oophorectomy (BSO), once a woman has completed childbearing, is the
most effective risk reduction strategy for ovarian cancer for individuals with a
BRCA mutation [49]. Studies have shown that a prophylactic BSO reduces a
woman’s risk of developing ovarian, peritoneal, and fallopian tube cancer by up to
90%. Furthermore, prophylactic BSO reduces the risk of breast cancer by almost
50% by eliminating hormone production that may contribute to development of
cancer [49,50,51].
A recent study showed that with no intervention the survival rate of BRCA
carriers was between 53-71%. They also found that prophylactic oophorectomy by
age 40 paired with either screening (MRI and mammography) or prophylactic
mastectomy at age 40 increased survival by 24% for BRCA1 carriers and by 11% for
BRCA2 carriers [52].
Chemoprevention, the use of agents to delay or reduce the risk of cancer or
recurrence, is another management tool that has been used for risk reduction in
individuals with BRCA mutations. Studies have reported that individuals with a
14

BRCA2 mutation may have up to a 62% reduced risk for breast cancer following a
five-year tamoxifen course [53]. Individuals with BRCA1 mutations generally have
ER/PR negative tumors and would therefore not benefit from chemoprevention.
Alternatively, aromatase inhibitors, anti-estrogenic agents are also being
investigated to determine the effects despite a woman’s estrogen receptor status.
However, studies have reported that aromatase inhibitors may have associated
risks such as hot flashes and increased incidence in bone fractures. The same study
found that these aromatase inhibitors also reduce the risk of developing
contralateral breast cancer [54]. Similarly oral contraceptive use has been associated
with risk reduction for ovarian cancer in both BRCA1 and BRCA2 carriers. Small
studies have shown that ovarian cancer risks in BRCA1 mutation carriers may be
reduced by up to 50% with the use of an oral contraceptive. Similarly, ovarian
cancer risks for BRCA2 carriers were shown to be reduced by up to 60% in this
study population [55,56]. Through the understanding of the inheritance of the
BRCA mutations, associated cancer risks, different testing options, and screening
and management guidelines, one can begin to appreciate the importance of
adequately individuals at risk of carrying BRCA mutations.

In 2009, the American Congress of Obstetricians and Gynecologists (ACOG) and
the Society of Gynecologic Oncologists (SGO) partnered to a release a practice
15

bulletin regarding clinical management guidelines for Obstetricians and
Gynecologists with regards to HBOC. This bulletin, based off the 2008 version of
the NCCN guidelines, first outlined how to identify individuals who should be
offered a hereditary risk assessment. The bulletin states that “evaluating a patient’s
risk for hereditary breast and ovarian cancer syndrome should be a routine part of
obstetric and gynecologic practice” [59].
The ACOG Practice bulletin also discusses the best testing strategies for
individuals at risk of carrying a BRCA mutation. They recommend that the when
possible, genetic testing should begin with the “affected individual”. For this, full
sequencing of the BRCA1 and BRCA2 genes is advised. Once a specific mutation is
identified or if the specific mutation is known in the family then single-site testing is
recommended. Furthermore, ACOG states that for specific populations where
founder mutations are known (Ashkenazi Jewish, French Canadian, Icelandic,
Netherlandic, and Swedish) common mutation testing versus full sequencing
should be offered [59]. While the aforementioned guidelines are representative of
the general consensus with regards to identifying at risk individuals, the question
still remains as to who should be identifying these individuals.

Previous Studies
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Several studies have looked at the utilization of BRCA testing among
physicians in the United States and abroad [60 ,62]. In a study of 1500 primary care
physicians, 87% of respondents were aware of the availability of BRCA testing
while only 25% reported to having ordered it in the past year. Furthermore,
obstetricians and gynecologist, which made 16.7% of the surveyed population, were
in fact the most likely of all physician specialties to order the BRCA testing as
compared to other specialties [62]. Another study, which surveyed non-academic
physicians who have ordered BRCA testing, found that a third of obstetricians and
gynecologists counsel the patient without the assistance of genetic counselor [60].
Other studies have specifically focused on the knowledge and attitudes of
gynecologists with regards to HBOC. In a study of 172 gynecologists in Germany,
62% indicated that they would feel comfortable performing basic genetic counseling
for a high risk patient but a majority, 94%, indicated the desire for more information
on BRCA genetics [63]. Another study in the United States specifically looking at
obstetricians and/or gynecologists residents and their knowledge of both HBOC
and Lynch Syndrome, a hereditary condition caused by a mutations in the
mismatch repair genes which increase the risks for colon and endometrial cancers,
elucidated some areas of deficiency in knowledge with regards to how HBOC is
inherited in families and what other cancer risks are associated with mutations in
the BRCA1 and BRCA2 genes. Of 157 study participants, 51% incorrectly indicated
17

that colon cancer was associated with HBOC and only 62% correctly identified that
a mutation could be inherited from paternal relatives. In one recent study, a group
of 1,878 physicians from across the United States were surveyed and asked to
identify individuals who should be referred for genetic testing and counseling
based on the information provided in a vignette. Of those physicians that
participated 18.1% identified themselves as obstetrician and/or gynecologists. This
study found that among obstetricians and/or gynecologists only 57.3% were able to
accurately identify a woman at a high risk for carrying a BRCA mutation [64].

Significance of this study
Hereditary breast and ovarian cancer syndrome is a well-defined and
studied genetic condition. With the availability and documented benefits of cancer
screening, early assessment of cancer risks and evaluation for hereditary cancer
syndromes such as HBOC, it is important for implementing personalized screening
and prevention guidelines for those found to have a BRCA mutation. These early
interventions can ultimately reduce morbidity and mortality for both breast and
ovarian cancer patients and can also assist in identifying other family members who
may be at risk and could benefit from such information. While many women do not
follow up with a primary care physician on a regular basis, some studies have
shown an increase in the number of visits to their obstetricians and/or gynecologists
18

[65]. Therefore, obstetricians and/or gynecologists are in a position to identity
patients who may benefit from BRCA testing. This study is designed to assess
knowledge of HBOC and BRCA testing, attitude towards BRCA testing, and
utilization of BRCA testing among obstetricians and/or gynecologists in the greater
Houston area. With the information attained from this study, we hope to be able to
begin to address areas where educational modules and clinical protocols may
benefit patient care.
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MATERIALS AND METHODS
Study Design
This study was conducted via questionnaire to determine the current knowledge,
attitudes, and utilization of the Houston area obstetricians and/or gynecologists
(Ob/Gyns) with regards to HBOC and BRCA testing. Specifically the aims of this
study were to:
1. Determine the knowledge of Ob/Gyns with regards to hereditary breast and
ovarian cancer syndrome and BRCA testing.
2. Assess how Ob/Gyns are utilizing BRCA testing.
3. Determine what Ob/Gyns feel their role is with regards to BRCA testing.

Database
All the data obtained from the surveys was entered into a Microsoft Excel
2010 spreadsheet. Each survey was assigned a unique identification number to
ensure that the responses were anonymous. All of the information was then coded
in order to be entered into the statistical software package for higher-level analysis.
An overall knowledge score was calculated for each participant that answered the
knowledge based questions and this information was also used for multivariate
analysis.

20

Study Approval
The survey was approved by the Institutional Review Board at the
University of Texas Health Science Center at Houston Graduate School of
Biomedical Sciences (IRB# HSC-GSBS-11-0328). Additionally, a separate IRB
approval was obtained from Woman’s Hospital of Texas (264839-1); which was also
accepted at Kelsey-Seybold Clinic for survey distribution. Approval to begin survey
collection was received by the Memorial Hermann Clinical Innovation & Research
Institute in order to administer the surveys at the affiliated Memorial Hermann
Hospital System’s institutions. Two institutions, Methodist Hospital and St.
Joseph’s Hospital, accepted the aforementioned UT IRB for survey distribution.

Study Population
The study was distributed to 268 physicians across institutions which
included: Memorial Hermann Texas Medical Center, Memorial Hermann Katy,
Memorial Hermann Memorial City, Memorial Hermann Southwest, Woman’s
Hospital, Kelsey-Seybold Clinic, Methodist Hospital Texas Medical Center, and St.
Joseph’s Hospital. The inclusion criteria for this study was board certified or board
eligible Ob/Gyns in the Houston area; which excluded all other physicians
practicing in other specialties and Ob/Gyns still in residency. The survey was only
available in English and there was no opportunity for translation.
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Survey/ Questionnaire
A questionnaire (Appendix A) was created in order to assess a sample of
Ob/Gyns in the greater Houston area. A review of the literature did not identify a
validated questionnaire specifically evaluating Ob/Gyn’s knowledge, attitudes,
or utilization of BRCA testing, therefore, an instrument was created. The survey
was revised by committee members through several phases to determine whether it
was clearly worded and appropriately structured to gather the desired
information. Experts within the fields relevant to the questionnaire reviewed the
survey in order to assess content and validity.
A cover letter explaining the nature of the survey and serving as the consent
document was included with each survey (See Appendix B). Participation in the
survey served as consent.
The questionnaire consisted of 40 questions and took about 15 minutes to
complete. The questionnaire was divided into four main sections: (1) demographics,
(2) attitude toward BRCA testing, (3) utilization of BRCA testing and (4) knowledge
of BRCA testing.
1.

Demographics: This section consisted of seven questions to gather gender,
since the completing their residency, area of practice, practice setting, and
number of patients typically seen per week. Questions in this section were
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multiple choice and free response where applicable.
2.

Attitudes toward BRCA testing: This section consisted of 5 questions
regarding the overall comfort of identifying patients at risk of carrying a BRCA
mutation, assessing participants’ views on whether identifying at risk patients
was on of their practice responsibilities, and determining barriers which could
potentially prevent participants from ordering testing. Questions in this section
were yes/no questions, multiple choice (some limited to one response while
others were open to several responses), a five point likert scale to assess
comfort (very uncomfortable, uncomfortable, uncertain, comfortable, and very
comfortable), and free response where applicable.

3.

Utilization of BRCA testing: This section consisted of seven questions designed
to assess how often participants identified, initiated a conversation, ordered
testing, or received questions related to hereditary breast and ovarian cancer
and BRCA testing. Furthermore, this section served to gather information
about participants’ referral patterns once an individual with a suspected BRCA
mutation was identified. Answers in this section were gathered via a five point
likert scale to assess how often each of the aforementioned scenarios arose. The
likert scale assessed the average number of times per month each scenario
arose with the following choices: never, rarely (<1 time/mo), sometimes (1-2
times/month), often (3-4 times/month), and on a regular basis (>= 5 times/mo).
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A multiple choice question was used to assess the participants’ referral
patterns.
4.

Knowledge of BRCA testing: This section consisted of twenty questions to
assess the overall knowledge of each participant with regards to hereditary
breast and ovarian cancer and BRCA testing. The questions in this section were
yes/no choices with simple example patients to determine if the survey
participant could correctly identify those at risk of having a BRCA mutation.
Similarly, yes/no questions were used to determine knowledge of cancers
associated with hereditary breast and ovarian cancer syndrome. Finally a series
of multiple choice questions were used to assess the knowledge about the
lifetime risks associated with hereditary breast and ovarian cancer syndrome
and the type of testing that would be appropriate given a particular patient’s
personal and family background.

At the conclusion of the survey, there was a free response box designed for any
comments regarding the survey or hereditary breast and ovarian cancer and BRCA
testing in general.

Survey/ Data Collection
Two different methods of distribution were used in order to attempt to
maximize the response rate. The first method was an online survey, with direct
24

contact information gathered from the respective hospital system email databases.
A direct link to the survey, embedded in the body of the message, was sent out to
all obtained email addresses. A follow up reminder email was sent out to all
individuals for participation about one week after the initial distribution. The
electronic version of the survey was created in such a way that individuals that
participated in this format were allowed to skip over questions, but could not go
back to change answers once the question had been submitted or skipped. IP
addresses were tracked so that the survey could theoretically only be submitted
once from a given computer. While individuals could theoretically use different
computers to submit several responses, this would be highly unlikely.
The second distribution method was via a hard copy of the survey with in
person contact. This contact was made through the attendance of various monthly
hospital meetings. Individuals that had previously completed the online version of
the survey were asked not to take part at these visits, but there was no way to
ensure that an individual did not complete both formats of the survey.
Both hard copy and digital delivery methods were distributed between
October 2011 and February 2012. The institutions, in which one or both methods of
delivery were utilized, included: Memorial Hermann Texas Medical Center (both
online and in person distribution), Memorial Hermann Katy (in person
distribution), Memorial Hermann Memorial City (both online and in person
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distribution), Memorial Hermann Southwest (in person distribution), Woman’s
Hospital (online and in person distribution), Kelsey-Seybold Clinic (online
distribution), Methodist Hospital Texas Medical Center (online distribution), and St.
Joseph’s Hospital (in person distribution).

Statistical Analysis
Both univariate and multivariate analyses were performed on all applicable
variables using the statistical software package STATA (v. 11, College Station, TX).
Descriptive charts and graphs were created using Microsoft Excel. A comparison
between groups was performed using contingency test (χ2 or Fisher exact tests),
Mann-Whitney sign-rank or Kruskal-Wallis tests where appropriate. Comparisons
between paired groups were performed using Wilcoxon signed ranks test. Linear
and logistic regression models were used to assess any linear trends over a series of
ordinal categories. Spearman’s correlation tests were utilized to assess the degree of
correlation between two continuous variables. Tests were considered statistically
significant at p<0.05.
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RESULTS
Survey Response
The total number of physicians present at meetings and/or providing an
email address for access for survey distribution was 232. Of the surveys distributed
online, 18 (6.7%) were invalid emails and were returned immediately. There were
ninety-two surveys that were returned as completed. Fifty nine of these were hard
copies of the survey distributed at various departmental meeting. The rest, thirty
three, were online versions of the survey distributed through the online Survey
Monkey database. Of the thirty three surveys completed online, two were opened
online but no questions were attempted. An additional seven surveys (2.6%) were
excluded. Of these seven, one was filled in by an RN, four were filled by physicians
in residency, one was filled by a visiting foreign medical physician, and one
participant only filled out the demographics section leaving the rest of the survey
blank. Of the 92 surveys returned, 83 were used in statistical analysis, which
resulted in a (30.97%) response rate overall. In both formats of the survey
respondents were selective in which questions they answered, which resulted in
varying numbers of total responses for some questions.
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Part I: Demographics
Fifty three percent (n=44) of respondents were female, and forty seven
percent (n=39) were male (Figure 1).
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Of the eighty three participants, seventy six (92%) were board certified in
obstetrics and gynecology, while the remaining seven (8%) were not. The
participants were asked to indicate the years since the completion of their primary
residency. The average years reported was 17.89 years with a range from 0-47 years.
This was consistent with the median of the group, which was found to be eighteen
years.
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Seventy four (89.2%) participants indicated that they were not boarded in
any other specialty, while nine (10.8%) indicated that they were. Of those, three
(33.3%) were board certified in gynecologic oncology only, one (11.1%) was board
certified in obstetrics only, two (22.2%) were boarded in gynecologic oncology, one
(11.1%) was boarded in maternal fetal medicine, one (11.1%) was boarded in
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reproductive endocrinology, and one chose no to indicate an additional subspecialty.

Sixty nine (83%) participants identified their primary practice area as general
obstetrics and/or gynecology, four (5%) were gynecology only, three (4%) as
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gynecologic oncology, two (2%) as maternal fetal medicine, two (2%) as
reproductive endocrinology, and three (4%) as urogynecology.
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The majority of participants, fifty six (67.5%), reported that they work in a
private practice setting. Those that indicated private practice were then asked to
indicate the average number of Ob/Gyns in their group. The average number of
Ob/Gyns reported was 9.36 (SD 10.59). There were twenty seven (32.5%)
participants who reported to work in an academic institution.
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The respondents were asked to identify the number of patients they see in
the outpatient setting during an average week. They were given five ranges and
about half (46%) stated that they see between 51-100 patients per week. A quarter of
respondents reported to see between 101-150 patients per week, while 19% stated
they saw less than 50 per week. Only 6% and 4% of respondents reported to seeing
151-200 and greater than 200 patients per week, respectively.
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Part II: Attitude toward HBOC and BRCA testing
The majority (57%) of respondents felt comfortable in identifying patients
who are at an increased risk of carrying a BRCA mutation. An additional 20% of
respondents indicated that they felt very comfortable with this task. The remaining
10%, 4%, and 8% of respondents were very uncomfortable, uncomfortable, or
uncertain, respectively, with regards to identifying patients at an increased risk to
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carry a BRCA mutation.
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Each participant was asked to evaluate a set of two statements. The first
statement asked if he/she felt that it was one of their practice responsibilities to
identify patients at risk of having a BRCA mutation. The majority (92.7%, n=77) of
respondents indicated yes, 6% (n=5) indicated no, and 1.2 % (n=1) chose to not
answer. The second statement asked if he/she felt that patient management would
change if the patient was found to be a carrier of a BRCA mutation. Here 87.9%

(n=73) indicated yes, 8.4% (n=7) indicated no, and 3.6% (n=3) chose not to answer.
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There were seven respondents that indicated that identifying patients who
may carry a BRCA mutation was one of their practice responsibilities and in a
subsequent question indicated that their management of a patient would not
change if the patient carried a BRCA mutation. Conversely, five respondents that
indicated that identifying patients who may carry a BRCA mutation was not one of
their practice responsibilities subsequently indicated that their management of a
patient would change if the patient carried a BRCA mutation. A wilcoxon signedrank test indicated that there was no significant difference between these two
groups (z=0.5637). Additionally two respondents that indicated that identifying
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patients who may carry a BRCA mutation was one of their practice responsibilities
chose not to respond to the subsequent question. There was one respondent that
chose not to answer either of the aforementioned questions.
The next question asked respondents to identify who they feel has the
primary responsibility of identifying patients that are at risk of carrying a mutation
in either the BRCA1/2 gene. Respondents taking the survey online were limited to
only one answer choice, but it was not possible to prevent those taking the paper
version of the survey from indicating more than one response. Each of the
following responses was not mutually exclusive. The majority of respondents
(84.3%, n=70) indicated that Ob/Gyns should have the primary responsibility of
identifying these patients. Primary care physicians were identified by 26.5% (n=22)
as the second highest group believed to be responsible for identifying these
patients. This was followed by 10.8% (n=9) of respondents choosing oncologists,
3.6% (n=3) choosing radiologists, and 1.2% (n=1) chose other, with a written
comment indicating that family members should have the primary role of
identifying individuals at risk of having a BRCA mutation.

39

The final question in this section asked respondents to identify barriers they feel
prevent the ordering of BRCA genetic testing. Multiple answers were accepted on
both versions of the survey, indicating that the answer choices were not mutually
exclusive. Most (80.7%, n=67) respondents indicated that the cost of testing was a
barrier in genetic testing. Possibility of insurance discrimination was the second
most chosen barrier by 37 respondents (44.6%). Additionally, time constraints in
clinic (31.3%, n=26), lack of patient interest/uptake (22.9%, n=19), lack of knowledge
regarding which patients are eligible for testing (8.4%, n=7), and feeling that BRCA
testing is not an important aspect for their patient care (1.2%, n=1) where all
indicated by the respondents as perceived barriers. Eight respondents (9.6%) also
stated “other” as a potential barrier for ordering BRCA testing, and wrote in:
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1. Physician asking questions
2. Usually refer to genetic counseling
3. I refer back to the PCP
4. Insurance denial
5. Refer to our high risk clinic for counseling rather than ordering the testing alone
6. There are often other greater priorities at the visit
7. Uncertain indications, understanding and interpretation of the test
8. I have a great go to person in my multi disciplinary practice, so if risk or inquiry I
send the patient to him
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Part III: Utilization of BRCA testing
All respondents answered the following series of questions by indicating
their answer choice on a likert scale for the frequency of each situation per month.
The answer choices were “never”, “rarely” (<1 time/month), “sometimes” (1-2
times/month), “often” (3-4 times/month), and “on a regular basis” (≥ 5
times/month). The first question asked how often the respondent saw a patient at
an increased risk for HBOC. The majority (32.5%, n=27) indicated rarely, 30.1%
(n=25) indicated sometimes, 22.9% (n=19) indicated often, 8.4% (n=7) indicated on a
regular basis, 1.2% (n=1) indicated never, and 4.8% (n=4) chose not to respond. The
frequency of seeing patients at an increased risk as reported in these responses and
the number of patients seen by that physician in a typical week was not correlated
(r=0.16). The second question asked how often the respondent received questions
from patients about the heredity of breast cancer. The majority (39.8%, n=33)
indicated rarely, 24.1% (n=20) indicated sometimes, 15.7% (n=13) indicated often,
9.6% (n=8) indicated on a regular basis, 6% (n=5) indicated never, and 4.8% (n=4)
chose not to respond. The correlation between the responses given and the number
of patients seen in a typical week was poor (r=0.12). The third question asked how
often the respondent received questions from patients about BRCA1/2 testing. The
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majority (43.4%, n=36) indicated rarely, 27.7% (n=23) indicated sometimes, 9.6%
(n=8) indicated often, 3.6% (n=3) indicated on a regular basis, 10.8% (n=9) indicated
never, and 4.8% (n=4) chose not to respond. The fourth question asked how often
the respondent initiated a conversation regarding genetic testing for BRCA1/2 with
a patient. The majority (30.1%, n=25) indicated sometimes, 19.3% (n=16) indicated
rarely, 21.7% (n=18) indicated often, 19.3% (n=16) indicated on a regular basis, 3.6%
(n=3) indicated never, and 4.8% (n=4) chose not to respond. The fifth question asked
how often the respondent ordered genetic testing for BRCA1/2. The majority (43.4%,
n=36) indicated rarely, 14.4% (n=12) indicated sometimes, 6% (n=5) indicated often,
6% (n=5) indicated on a regular basis, 22.9% (n=19) indicated never, and 7.2% (n=6)
chose not to respond. The final question in this series asked how often the
respondent referred a patient to a genetic counselor or other specialist in order to
discuss genetic testing for BRCA1/2. The majority (39.8%, n=33) indicated rarely,
21.7% (n=18) indicated sometimes, 9.6% (n=8) indicated often, 7.2% (n=6) indicated
on a regular basis, 14.4% (n=12) indicated never, and 7.2% (n=6) chose not to
respond.
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Next we asked respondents to indicate what they would do after identifying
patients at risk of carrying a BRCA1/2 mutation. Respondents could choose multiple
answers, indicating that the answer choices were not mutually exclusive. The
majority (53%, n=44) indicated that they would discuss HBOC and order BRCA
testing themselves. 48.2% (n=40) of respondents indicated that they would refer the
patient to a genetic counselor for risk assessment and possible BRCA testing. 9.6%
(n=8) of respondents indicated that they would refer a patient to another specialist,
including: oncologist (n=2), hematology and oncology (n=1), breast center (n=1), and
specifically a MDAnderson Cancer Center genetic counselor (n=1). Three
respondents did not indicate to which specialist they would refer. Additionally, one
respondent (1.2%) indicated that they would refer the patient back to their PCP and
another respondent (1.2%) indicated that they would do nothing, because he/she
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did not feel that knowing whether or not a patient carries a mutation in BRCA
would change the management of the patient.

Part IV: Knowledge
The first group of questions consisted of patient scenarios and respondents
were asked whether each patient would be at an increased risk for having a
mutation in the BRCA1 or BRCA2 gene. The first patient scenario was a patient who
was diagnosed with breast cancer at 45 years but has no other family history of
breast cancer. The majority of respondents, 62.7% (n= 52), correctly indicated that
this patient would be at an increased risk, while 27.7% (n=23) indicated that this
patient would not be at an increased risk and 9.6% (n=8) chose not to respond.
The second patient scenario was a patient who was diagnosed with ovarian cancer
at the age of 55 years. The majority of respondents, 53% (n= 44), correctly indicated
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that this patient would be at an increased risk, while 36.1% (n=30) indicated that
this patient would not be at an increased risk and 10.8% (n=9) chose not to respond.
The third patient scenario was a patient who is Ashkenazi Jewish and was
diagnosed with breast cancer at the age of 60 years. The majority of respondents,
69.9% (n= 58), correctly indicated that this patient would be at an increased risk,
while 20.5% (n=17) indicated that this patient would not be at an increased risk and
9.6% (n=8) chose not to respond. The fourth patient scenario was a patient whose
brother was diagnosed with breast cancer. The majority of respondents, 81.9% (n=
68), correctly indicated that this patient would be at an increased risk, while 7.2%
(n=6) indicated that this patient would not be at an increased risk and 10.8% (n=9)
chose not to respond. The fifth patient scenario was a patient whose paternal
grandmother was diagnosed with breast cancer at the age of 50 and whose paternal
aunt was diagnosed with breast cancer at 49 years old. The majority of respondents,
69.9% (n= 58), correctly indicated that this patient would be at an increased risk,
while 18.1% (n=15) indicated that this patient would not be at an increased risk and
12% (n=10) chose not to respond. The sixth patient scenario was a patient whose
paternal cousin was diagnosed with endometrial cancer at 45 and whose paternal
aunt was diagnosed with colon cancer at 51 years The majority of respondents,
48.2% (n= 40), correctly indicated that this patient would not be at an increased risk,
while 42.2% (n=35) indicated that this patient would be at an increased risk and
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9.6% (n=8) chose not to respond. The seventh patient scenario was a patient who
has a family member with breast cancer, regardless of age. The majority of
respondents, 77.1% (n=64), correctly indicated that this patient would not be at an
increased risk, while 10.8% (n=9) indicated that this patient would be at an
increased risk and 12% (n=10) chose not to respond. The final patient scenario was a
patient whose mother was diagnosed with breast cancer at 60 years and whose
maternal grandmother was diagnosed with breast cancer at the age of 70 years. The
majority of respondents, 45.8% (n= 38), incorrectly indicated that this patient would
be at an increased risk, while 44.6% (n=37) correctly indicated that this patient
would not be at an increased risk and 9.6% (n=8) chose not to respond.
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The second group of knowledge questions consisted of a list of cancers and
the respondents were asked to identify whether each particular cancer was
associated with HBOC. The first cancer listed was breast cancer, which is associated
with HBOC. The majority of respondents, 95.2% (n=79), indicated correctly that
breast cancer is associated with HBOC while 4.8% (n=4) chose not to answer. The
second cancer listed was colon cancer, which is not associated with HBOC. The
majority of respondents, 53% (n=44), incorrectly indicated that colon cancer is
associated with HBOC while 31.3% (n=26) indicated correctly that it is not
associated and 15.7% (n=13) chose not to answer. The third cancer, which is
associated with HBOC, was high grade serous or endometrioid ovarian cancer. The
majority of respondents, 78.3% (n=65), correctly indicated that that high grade
serous or endometrioid ovarian cancer is associated with HBOC while 10.8% (n=9)
incorrectly indicated that it is not associated, and 10.8% (n=9) chose not to answer.
Next, participants were asked to evaluate mucinous ovarian cancer, which is not
associated with HBOC. The majority, 42.2% (n=35), correctly indicated that
mucinous ovarian cancer is not associated with HBOC, while 38.6% (n=32)
indicated that this cancer is associated with HBOC, and 19.3% (n=16) chose not to
answer. The next cancer listed was prostate cancer, which is associated with HBOC.
The majority, 50.6% (n=42), of participants incorrectly chose that prostate cancer is
not associated with HBOC. Only 24.1% (n=20) correctly identified prostate cancer as
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being associated with HBOC, and 25.3% (n=21) chose not to answer. The next cancer
listed was uterine cancer, which is not associated with HBOC. The majority, 55.4%
(n=46), of participants correctly indicated that uterine cancer was not associated
with HBOC, while 25.3% (n=21) of respondents incorrectly indicated that uterine
cancer is associated with HBOC, and 25.3% (n=16) chose not to answer. The final
cancer listed was fallopian tube cancer, which is associated with HBOC. The
majority of respondents, 59% (n= 49), correctly identified that fallopian tube cancer
is associated with HBOC, while 24.2% (n=20) indicated that it was not, and 7.2%
(n=14) chose not to respond.
The majority (86.6, n=58) of respondents that indicated that they would change
their management of a patient if the patient carried a BRCA mutation were able to
accurately identity ovarian cancer as being an HBOC associated cancer. However,
nine respondents (13.4%) did not identify ovarian cancer as being an HBOC
associated cancer. Similarly the majority (69.4%, n=43) of respondents that indicated
that they would change their management of a patient if the patient carried a BRCA
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mutation were able to accurately identity fallopian tube cancer as being an HBOC
associated cancer, while 30.6% (n=19) were not.
Respondents were asked what the lifetime risk for developing breast cancer is
for a woman with a known BRCA mutation. Less than half (44.6%, n=37) correctly
identified that the lifetime risk is up to 88%. About one third of respondents (30.1%,
n=25) indicated that the risk is up to 44%, 9.6% (n=8) indicated that the risk is up to
22%, 1.6% (n=1) indicated that the risk is virtually 100%, 6%(n=5) indicated that they
did not know, and 8.4% (n=7) chose not to answer.
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Respondents were asked what the lifetime risk for developing ovarian cancer is
for a woman with a known BRCA mutation. About half (54.2%, n=45) correctly
identified that the lifetime risk is up to 44%. About one fifth of respondents (19.3%,
n=16) indicated that the risk is up to 22%, 12% (n=10) indicated that the risk is up to
88%, 9.6% (n=8) indicated that they did not know, and 4.8% (n=4) chose not to
answer.
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Respondents were asked to identify the risk of inheritance for BRCA
mutations if a known first-degree relative had an identified mutation. About half
(48.2%, n=40) correctly identified the risk as 50%. About one third of respondents
(28.9%, n=24) indicated the risk as 25%, and 1.6% (n=1) indicated the risk as 100%.
There were two respondents (2.4%) that indicated that the risk level was dependent
upon whether the maternal or paternal relative was the relative with the known
mutation. Additionally, 14.5% (n=12) indicated that they did not know and 4.8%
(n=4) chose not to answer.
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Respondents were asked to identify the pattern of inheritance for BRCA
mutations. The overwhelming majority (83.1%, n=69) correctly identified that
mutations could be inherited from either the patients mother or father. Only 4.8%
(n=4) indicated that a mutation could only be inherited from the patient’s mother.
Another 6% (n=5) stated they did not know, while an additional 6% (n=5) chose not
to respond.
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The final knowledge question asked the respondents to identify the type of
testing most appropriate for an Ashkenazi Jewish patient with a known familial
mutation. Only 6% (n=5) correctly identified that multisite BRACAnalysis® would
be the most appropriate. The majority of participants, 42.2% (n=35), stated that they
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did not know, while 20.5% (n=17) indicated that single site BRACAnalysis® would
be the most appropriate. Another 19.3% (n=16) indicated that comprehensive
BRACAnalysis® would be most appropriate and 6% (n=5) stated that BART testing
was the most appropriate for the given patient. Additionally, 6% (n=5) chose not to
respond.

Respondents were allowed to provide any comments with regards to this
survey, identifying patients at risk for HBOC or BRCA testing. There were several
respondents that opted to provide feedback, which included:
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1. “Points out need to clarify type of BRCA analysis available and which one to
use”
2. “It borders on the criminal that Myriad Lab was able to patent this gene and
to be able to charge the exorbitant amount of money they are able to get for
this testing”
3. “Insurance coverage is still lousy”
4. “Should probably cover colaris testing as well”
5. “Can we receive the answers and/or source to read”
6. “I obviously don't know as much as I thought I did”

Knowledge Score:
An overall knowledge score was calculated for each participant. Each correct
answer received one point value, with a maximum of 20 total points. The average
score attained by all respondents was 11.28 (56.4%), with a range of 0-18 total
points. The median knowledge score was calculated for each of the practice settings.
Gynecologic oncology (n=3) was the highest scoring group with a median score of
17(85%). Reproductive endocrinology was the next highest group (n=2) with a
median score of 14.5(72.5%). Urogynecology (n=3) had a median of 12 (60%),
Ob/Gyns (n=69) had a median of 11 (55%), gynecologist only (n=3) had a median
score of 10 (50%), and MFM (n=2) had the lowest median score of 9(45%).
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An arbitrary cut off was set at 70% for knowledge score and respondents
were subsequently grouped into “high scorers” (above 70%) and “low scorers”
(below 70%). The majority (69.6%, n=48) of Ob/Gyns were “low scorers”. Again the
high and low scorers were stratified by practice. All of the gynecology only, MFMs,
and urogynecologists surveyed were in the “low scorers” category. All of the
gynecologic oncologists and reproductive endocrinologists surveyed were in the
“high scorers” category.

Stratification between “high and low scorers” and practice setting showed
that 67.9% (n=38) of those in the private practice were “low scorers”. Similarly,
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70.4% (n=19) of respondents in the academic institution practice setting were found
to be “low scorers”. These distributions were not statistically significant (p=0.82).
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Both knowledge score and “high scorers” were evaluated with comparison
to years since the completion of the respondents’ primary residency. A linear
regression between overall knowledge score and years since completion of
residency demonstrated a significant decrease in knowledge over time (β coefficient
=-0.082, p=0.032). Despite the significant trend, there was considerable variability in
knowledge score over time since residency and these two variables were poorly
correlated (r=-0.24). Furthermore, a logistic regression performed between “high
scorers” and the years since respondents’ completion of primary residency, found a
0.95 odds ratio (95% CI: -0.156 to -0.007), i.e. for every unit increase in years since
primary residency, the odds of being a “high scorer” decrease by 5%.
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A regression between “high scorers” and the number of patients seen was
not statistically significant (p=0.273). About two-thirds of respondents (68.8%, n=11)
that indicated they saw fewer than fifty patients in a typical week were found to be
“low scorers”. 65.8% (n=23) of respondents that indicated they saw between 51-100
patients were found to be “low scorers”. The majority (81%, n=17) of respondents
that indicated they saw between 101-150 patients were found to be “low scorers”.
Sixty percent (n=3) of respondents that indicated they saw between 151-200 patients
were found to be “low scorers”, while all (100%, n=3) respondents that indicated
they saw over two hundred patients were found to be “low scores”.

60

A linear regression between knowledge score and comfort in identifying
patients demonstrated a non-significant decrease of 0.2% for every unit increase in
comfort level (β coefficient = -0.20, p=0.617). High scorers and low scorers were also
stratified by comfort. Three quarters (75%, n=6) stated they were very
uncomfortable and were found to be “low scorers”. Similarly 66.67% (n=2) of
respondents that stated they were uncomfortable and 71.4% (n=5) of respondents
that stated they were uncertain with regards to comfort were found to be “low
scorers”. About three quarters (70.2%, n= 33) of respondents that indicated they
61

were comfortable and 58.8% (n=10) of respondents that indicated they were very
comfortable were found to be “low scorers”, answering less than 70% of knowledge
based questions correctly on the survey.

A chi squared test was performed between “high and low scorers” in the
knowledge portion of the survey and reported referral to a genetic counselor. No
statistically significant difference was found (p=0.486). About three quarters, 72.1%
(n=31), of respondents that stated they would refer to a genetic counselor after
identifying a patient at risk for having a BRCA mutation were “low scorers”.
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Furthermore, 65% (n=26), of respondents that would not refer to a genetic counselor
for further assessment and possible BRCA testing were “low scorers”.

Similarly when evaluating “high and low scorers” by those respondents that
would initiate a discussion and order testing themselves, 69.2% (n=27) of
respondents that chose this option were found to be low scorers. A chi-squared test
was performed and found to not be significant between the two groups (p=0.918).
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Ordering genetic testing:
The majority (73.7%, n=14) of respondents that indicated they typically never
order genetic testing indicated that they did not know what type of testing would
be most appropriate for an Ashkenazi Jewish woman with a known familial
mutation (Figure 27). One individual (5.3%) in this category indicated that they
would order comprehensive BRACAnalysis®, two (11.8%) correctly indicated they
would order multisite BRACAnalysis®, one (5.3%) indicated they would order
single site BRACAnalysis®, and one (5.3%) indicated they would order
BRACAnalysis® large rearrangement testing (BART). The majority (54.3%, n=19) of
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participants that indicated that they rarely (<1 time/month) order genetic testing
responded that they did not know what type of testing would be most appropriate.
Eight individuals (22.9%) in this category indicated that they would order
comprehensive BRACAnalysis®, six (17.1%) indicated they would order single site
BRACAnalysis®, two (5.7%) indicated they would order BRACAnalysis® large
rearrangement testing (BART), while no individuals chose the correct response of
multisite BRACAnalysis®. Of the eleven respondents that indicated that they
sometimes (1-2 times/month) order genetic testing, the majority (36.4%, n=4) of
respondents incorrectly identified comprehensive BRACAnalysis® as the most
appropriate testing option for the aforementioned patient. One individual (9.1%)
correctly indicated that they would order multisite BRACAnalysis®, while three
(27.3%) indicated single site BRACAnalysis®, one (9.1%) indicated they would order
BRACAnalysis® large rearrangement testing (BART), and two (18.1%) respondents
indicated that they did not know what type of testing would be most appropriate.
Of the five respondents that indicated that they often (3-4 times/month) order
genetic testing, the majority (80%, n=4) incorrectly identified single site
BRACAnalysis® as the most appropriate testing option, while only one individual
(20%) correctly indicated that they would order multisite BRACAnalysis®. No other
testing types were chosen by respondents in this category. For those respondents
that indicated that they order genetic testing on a regular basis (≥ 5 times/month),
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the majority (40%, n=2) incorrectly identified single site BRACAnalysis® as the most
appropriate testing option, while only one individual (20%) correctly indicated that
they would order multisite BRACAnalysis®, one individual (20%) indicated they
would order comprehensive BRACAnalysis®, and one individual (20%) indicated
they would order BRACAnalysis® large rearrangement testing (BART). There were
no respondents in this category that indicated that they did not know which testing
would be most appropriate. Finally, there were three individuals that previously
did not indicate how often they ordered testing. Of these individuals the majority
(66.7%, n=2) indicated that they would order comprehensive BRACAnalysis®, while
the other respondent (n=33.3%) indicated that they would order single site
BRACAnalysis®. Of all the respondents across the categories from never ordering
genetic testing to ordering genetic testing on a regular basis only five individuals
correctly identified that multisite BRACAnalysis® would be the most appropriate
test for an Ashkenazi Jewish woman with a known familial mutation (Figure 19).
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As shown in Figure 7 above, there was a five point likert scale for which
respondents could indicate their level of comfort in identifying patients that are at
an increased risk of carrying a BRCA mutation. Responses between comfort and
frequency of ordering genetic testing was further evaluated (Figure 28). Of the eight
respondents that indicated that they were very uncomfortable with identifying
patients at risk for carrying a BRCA mutation, the majority (75%, n=6) indicated that
they rarely ordered genetic testing. One respondent (12.5%) indicated that they
sometimes (1-2 times/month) order genetic testing, while another respondent
(12.5%) indicated that they order genetic testing on a regular basis (≥ 5
times/month). All respondents that indicated they were uncomfortable (n=3) also
indicated they never order genetic testing. There were seven respondents that
indicated they felt uncertain about their level of comfort in identifying patients at
risk for carrying a BRCA mutation. Of those respondents, the majority (42.9%, n=3)
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indicated that they never order genetic testing, while two (28.6%) indicated that
they rarely order genetic testing, one (14.3%) indicated that they sometimes order
genetic testing, and one (14.3%) respondent chose not to respond. The majority of
respondents (n=47) indicated that they were comfortable with identifying patients
at risk for carrying a BRCA mutation. Of these respondents, eight (17%) indicated
that they never order genetic testing, twenty four (51.1%) indicated that they rarely
order genetic testing, six (12.8%) indicated that they sometimes order genetic
testing, three (6.4%) indicated that they often ordered genetic testing, two (4.3%)
indicated that they order genetic testing on a regular basis, and four (8.5%) chose
not to respond. Finally, of respondents that indicated they were very comfortable
(n=17) with identifying patients at risk for carrying a BRCA mutation only two
(11.8%) indicated that they ordered genetic testing on a regular basis. Four (23.5%)
indicated that they never ordered genetic testing, four (23.5%) indicated that they
rarely ordered genetic testing, four (23.5%) indicated that they sometimes ordered
genetic testing, two (11.8%) indicated that they often ordered genetic testing, and
one (5.9%) chose not to respond.
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DISCUSSION
In this study, Houston area obstetricians and gynecologists were
asked about their knowledge, attitudes, and utilization of BRCA testing in
their practices. In 2009 the American Congress of Obstetricians and
Gynecologists (ACOG) released a practice bulletin, which identified the
necessity of evaluating a patient’s risk for HBOC as a routine part of obstetric
and gynecologic practice [59]. The purpose of this study was to capture the
current knowledge of both HBOC and BRCA testing among obstetricians and
gynecologist in the Houston area, to assess if and how they are utilizing
BRCA testing, and to determine what they feel their role is with regards to
BRCA testing.

Study population:
According to the 2008 Socioeconomic Survey of ACOG Fellows our
study is representative of the current membership with regards to gender
and years in practice [66]. The 2008 survey found that 44.6% of members
were female, with average years in practice of 17.59. Furthermore, the 2008
Socioeconomic Survey was consistent with our findings of practice setting
indicating that 73.6% of members work in a private practice with an average
of 6.3 physicians on site [66]. Our study found that 67.5% of respondents
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reported working in a private practice setting with a slightly higher average
of 9.36 physicians in their practice.
However, in this study the majority of respondents (83%) identified
their primary practice setting as general obstetrics and gynecology, while the
national survey found 67.9% of the total members identifying themselves in
this group. Similarly while our study population reported 5% to be
gynecologists only, 4% gynecologic oncologists, 2% were maternal fetal
medicine specialists, 2% were reproductive endocrinologists, and 4% were
urogynecologists; the national survey reports 17.9% gynecolgists only, 1.9%
gynecologic oncolgosits, 6.1% maternal fetal medicine specialists, 2.8%
reproductive endocrinologists, and .9% urogynecologists [66]. In this way, it
seems that the population surveyed was not representative of the
subspecialties found in the national reported members of ACOG, which can
most likely be attributed to our small sample size.

Perceived role and reported comfort in identifying at risk patients:
One of the study aims was to determine what obstetricians and
gynecologists feel their role is in regards to BRCA testing. An
overwhelming 92.7% of respondents indicated that they believe that
identifying patients at risk for HBOC is one of their practice responsibilities.
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Furthermore, the majority (84.3%) of respondents indicated that Ob/Gyns
have the primary responsibility of identifying patients at risk of carrying a
BRCA mutation (Figure 9). This is supported by the majority of responses
received when physicians were asked to indicate what they would do after
identifying a patient at risk for carrying a BRCA mutation. Respondents
indicated that once a patient at an increased risk of carrying a BRCA
mutation is identified, they would typically either discuss HBOC and
ordering BRCA testing themselves (53%) and/or refer the patient to a genetic
counselor (48.2%).
Our study shows that the majority (77%) of respondents felt very
comfortable or comfortable in identifying patients who are at an increased
risk of carrying a BRCA mutation. A study in 2008 reported a similar level
of comfort among 82 physicians, of which 18.3% reported gynecology as
their area of practice. This study used a 5-point scale, with 5 being the most
comfortable, to measure the group’s comfort when identifying potential at
risk patients for a hereditary cancer syndrome and discussing genetic
information. Their overall average comfort score was found to be 3.7 [67]. In
our study a similar 5-point likert scale ranging from very uncomfortable to
comfortable was used to assess how Ob/Gyns felt with identifying patients
who are at an increased risk of carrying a BRCA mutation. Were we to assign
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a 1-5 point value to each of our likert scale answer choices, giving very
uncomfortable a 1 point value, and very comfortable a 5 point value, we
could then calculate that our study found an overall comfort level of 3.85,
indicating that the results seen in our study are in line with previous studies
that evaluated comfort in identifying patients that may be at risk of carrying
a BRCA mutation.
It was initially hypothesized that those that stated a higher level of
comfort would have higher knowledge of HBOC and BRCA testing to
support their attitude. However, this study indicates that there is no positive
correlation between feeling comfortable identifying patients at an increased
risk and knowledge of HBOC and BRCA testing. In comparing the
knowledge score of each participant with regards to reported comfort in
identifying patients at risk (Figure 24), it is seen that the difference in
knowledge score is not statistically significantly different between
respondents that indicated they were very uncomfortable, uncomfortable,
uncertain, comfortable, and very comfortable. Furthermore, the majority
(58.8%)of physicians who reported feeling very comfortable in identifying
patients at an increased risk of carrying a BRCA mutation were found to be
low scorers (<70% accuracy) in the knowledge portion of the survey.
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Similarly, there was no statistical significance seen between comfort of
identifying at risk patients and the reported frequency of ordering genetic
testing. A quarter (25%) of respondents that stated they were very
uncomfortable with identifying patients that may be at an increased risk for
carrying a BRCA mutation indicated that they ordered genetic testing at least
1-2 times per month or more. About a third (35.3%) of respondents that
stated they were very comfortable with identifying patients that may be at an
increased risk for carrying a BRCA mutation indicated that they ordered
genetic testing at least 1-2 times per month or more.
The lack of a positive correlation seen between reported comfort in
identifying at risk patients, knowledge of HBOC/ BRCA testing, and
frequency of ordering genetic testing is clinically significant for practicing
physicians. These results indicate that respondents that felt very comfortable
or comfortable in identifying patients at a high risk for carrying a mutation
in BRCA1/2 were just as likely as those respondents that indicated they were
very uncomfortable or uncomfortable to answer below 70% of questions
correctly on the knowledge portion of the survey. Furthermore, these results
show that respondents indicate they are ordering testing even though they
may not have the knowledge to appropriately identify patients who are truly
at an increased risk for carrying a BRCA mutation. This raises two areas of
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concern. First, that they are ordering testing on patients who may not truly
be at an increased risk for carrying a mutation, thus wasting health care
dollars and increasing patient anxiety. Secondly, due to their lack of
knowledge, they are likely not correctly identifying patients who would
benefit from BRCA testing, thus patients who have HBOC are likely going
unidentified an therefore not receiving the screening/ surveillance and risk
reductions options that could potentially prevent them from developing life
threatening cancers.
The US Preventive Services Task Force (USPSTF) issued a practice
bulletin, which estimates that about 2% of women would meet the definition
for a patient at an increased risk of carrying a BRCA mutation [58]. With the
USPSTF bulletin in mind, we would expect that physicians that report seeing
between 51-100 patients per week to see about 4-8 patients at risk for HBOC
and thus carrying a mutation per month; acknowledging that this is just an
estimate as some patients may be seen for a follow-up visit in the same week
and thus counted twice. However, this study found that only about 10% of
respondents indicate that they see patients who they suspect may be at an
increased risk for HBOC on a regular basis (>5 times/month) (Figure 11). One
possible reason for this discrepancy in the data may be that physicians are
not in fact able to identify those patients that are at an increased risk of
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carrying a BRCA mutation. A previous study in 2003 of 172 gynecologists
further supports this conclusion. The 2003 study found that the majority of
participants felt comfortable with discussing HBOC with patients that are at
an increased risk of carrying a BRCA mutation, however, a third of
participants also indicated some uncertainty in their basic genetic knowledge
[63]. Furthermore, in our study, the majority of respondents (69.2%) that
indicated that they would discuss HBOC and order BRCA testing had a
knowledge score below 70% (Figure 26). Another previous study of 351
primary care physicians found similar results in that there was no
association between higher knowledge about breast cancer and having a
discussion about risk or ordering BRCA genetic testing [68]. This study
supports an ongoing trend of physician reported confidence in identifying
patients at risk of carrying a BRCA mutation, without adequate knowledge
to support such attitudes.

Utilization of BRCA testing:
About a quarter (26.4%) of respondents indicated that they order
genetic testing at least 1-2 times per month or more. Although the majority
of our respondents indicated that they do not regularly see a patient at
increased risk for HBOC, receive questions from patients about BRCA1/2
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testing, or order BRCA testing, some report that they do (Figure 11). About
8% of respondents reported to see a patient at increased risk for HBOC, 3.6%
reported to receive questions about BRCA1/2 testing, and 6% report to order
BRCA testing in a typical month.
There was no significant correlation between the number of patients
seen per week and the frequencies that physicians report to see patients an
increased risk for HBOC, to receive questions from patients regarding BRCA
testing or to actually order BRCA testing. One would have assumed that as
the number of patients seen in practice increased there would have been an
increase in the number of patients that would be identified as being at an
increased risk for HBOC, as well as an increase in the number of patients
asking question about BRCA1/2 testing, and subsequently the frequency of
ordering BRCA testing. The lack of correlation between these reported
practice frequencies and patient loads points to the possibility of other
influencing factors. One can conclude that given the overall poor knowledge
in regards to HBOC and BRCA testing identified through this study,
physicians may not feel that they have patients at an increased risk and
therefore do not order BRCA testing because they are unable to accurately
identify such patients.
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When comparing respondents that ordered genetic testing at least 1-2
times per month or more with the accuracy of identifying which test would
be the most appropriate for an Ashkenazi Jewish woman whose family has a
known mutation in a BRCA gene, there were only three (14.3%) respondents
who were able to correctly identify that multisite BRACAnalysis® was the
most appropriate for the given patient. Even with a known family mutation,
individuals of Ashkenazi Jewish ancestry should also be offered multisite
BRACAnalysis® due to the high carrier frequency of 1/40 found in the
Ashkenazi Jewish population. The multisite BRACAnalysis® will cover the
three most commonly found mutations that are present in this population.
The very low percentage of physicians who correctly answered this question
demonstrates the need for more education about which testing is most
appropriate based on patient presentation and risk factors. One of the
respondents clearly echoed this conclusion with a written comment stating
that the survey: “points out need to clarify type of BRCA analysis available
and which one to use.”
Another goal of this study was to understand what a physician would
do once he/she identified a patient that was at an increased risk of being a
BRCA carrier. The majority of respondents (53%) indicated that they would
discuss HBOC and order BRCA genetic testing themselves (Figure 12).
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However, as previously discussed, the majority of respondents in our study
also indicated that they rarely (<1 time per month) order genetic testing
(Figure 11).
While most (80.7%) respondents indicated that the cost of testing a
greatest barrier that prevented them from ordering BRCA genetic testing, just
under half (44.6%) felt that the possibility of insurance discrimination was
another barrier preventing them from ordering this testing (Figure 10).
Brandt et al (2008) found that about a third of their respondents also cited
insurance discrimination as a barrier in ordering genetic testing. In 2008, the
Genetic Information Nondiscrimination Act (GINA) was passed, which
protects all individuals and their families from being discriminated, both in
the workplace and by medical insurance companies, based on genetic
information. Education and awareness of GINA, therefore, could ultimately
eliminate this perceived barrier.
Just under half (48.2%) of physicians surveyed in this study indicated
that they would refer a patient with an increased risk of carrying a BRCA
mutation to a genetic counselor. Two previous studies found similar
incidences of referral to genetic counselors. A 2003 study of 172 German
gynecologists found that 58% of gynecologists surveyed recommended
genetic counseling to their patients, while only 34% had referred their
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patients to a genetic counselor within the past twelve months[63]. Another
study found that of the 214 physicians surveyed, 51% had referred to a
genetic counselor after identifying a patient at risk for HBOC [69]. Referring
to a genetic counselor was also further evaluated with relation to knowledge.
In our study, the majority of respondents (72.1%) that indicated that they
would refer to a genetic counselor had a knowledge score below 70% (Figure
25). It can be concluded that respondents that would refer to a genetic
counselor may see the benefits of utilizing a cancer genetic counselor that can
assist with discussing hereditary cancer and facilitate genetic testing.
However, identifying which patients may be at an increased risk of carrying
a BRCA mutation and therefore benefit from a referral to a genetic counselor
is the first step in order to utilize this service.

Knowledge regarding HBOC and BRCA testing
Our study shows that the overall knowledge of Ob/Gyns surveyed is
poor. An overall knowledge score was calculated for each participant. Out of
a total of twenty possible points, the mean for all respondents (n=83) was
11.28 with a range of 0-18 points. This point value corresponds to a mean
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accuracy rate of 56.4%. No respondents answered all of the knowledge
questions correctly. Not surprisingly, the highest scoring group was the
gynecologic oncologists as one would assume they regularly see ovarian
cancer patients in their practices. A similar European study, which evaluated
243 primary care physicians’ knowledge of HBOC via survey, found that the
Ob/Gyns in their study population had a lower average knowledge score of
38.6%. Oncologists in this same population were shown to have the highest
knowledge with regards to HBOC with an average 68.6% accuracy rate,
which is consistent with our study findings [70].
Knowledge regarding cancers that are associated with HBOC was
generally good across this study, with one notable exception. Respondents
could accurately indicate that both breast and ovarian cancers are associated
with HBOC, with 95.2% and 78.3% accuracy, respectively. However, only
24.1% of respondents could correctly identify that prostate cancer is
associated with HBOC. The risks of developing prostate cancer for males
who carry a BRCA mutation, specifically a BRCA2 mutation, can be as high
as 20%. Typically these cancers will be diagnosed at a younger age than in
the general population. Increased awareness of the association of prostate
cancer with HBOC is another area where education is needed. Another area
suggesting the need for increased education was highlighted when
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evaluating the respondent’s knowledge of the lifetime risks for developing
both breast and ovarian cancers for a woman with a know BRCA mutation.
About half of respondents could accurately indicate that a woman’s chance
for breast cancer may be as high as 88% and her chance for ovarian cancer
may be as high as 44% if she were a carrier of a BRCA mutation. While, about
40% of respondents underestimated a woman’s risk for developing breast
cancer and about 20% underestimated a woman’s risk for developing
ovarian cancer if she were a carrier of a BRCA mutation.
A statistically significant difference was found between the
knowledge score and the years since completion of the respondent’s primary
residency. Our data identified a decrease of approximately one point in the
overall knowledge score for every ten years since the completion of
residency. A study in 2010, which examined 157 Ob/Gyn resident’s
knowledge of HBOC and Lynch Syndrome, found that their knowledge was
slightly increased as compared to that which was found in our survey [71].
In this 2010 study, 51% of residents could accurately identify the autosomal
dominant pattern of inheritance of HBOC, 97% correctly identified ovarian
cancer as a being associated with HBOC, and 51% incorrectly identified that
colon cancer is associated with HBOC. Our study shows slightly decreased
knowledge in that: 49% of respondents could identify the autosomal
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dominant mode of inheritance of HBOC, 78.3% correctly identified ovarian
cancer as a being associated with HBOC, and 53% incorrectly identified that
colon cancer is associated with HBOC. According to our study those
individuals still in residency should have a slightly increased knowledge
score. Another study in 2000, which surveyed 564 ACOG fellows, further
supports this conclusion. This study found that younger physicians were
more likely to accurately answer questions in the knowledge portion of the
survey, which focused on both hereditary cancers and general genetic
information [72].
One possible argument could be made that residents score higher as
compared to board eligible/certified Ob/Gyns because of the residents’
connection with an academic setting. However, no significance was found in
our study to support this conclusion. When the knowledge score in this
study was arbitrarily stratified as “high scorers” (above 70% correct) and
“low scorers” (below 70% correct) it was seen that the there was no
significance between the primary practice setting and knowledge. In this
way it appears that those respondents that practiced at an academic
institution did not show an added benefit that may have otherwise been
presumed based on the connection with an academic institution, in
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comparison to those that indicated they primarily practiced in a private
practice.

Strengths and Limitations:
Since the ACOG practice bulletin in 2009, there have been no studies,
to our knowledge, that have addressed whether or not OB/ Gyns are in
agreement with these practice guidelines and how well they are adhering to
them. This study seems to be the first study that has focused on the attitudes,
utilizations, and knowledge of HBOC and BRCA in US Ob/Gyns. Through
the knowledge portion of the survey, we were able to identify areas that
need further attention for universal benefit for both physicians and patients.
These areas include both identifying patients that may be at an increased risk
for HBOC and identifying cancers that are associated with HBOC. This study
also captured the attitudes of physicians with regards to their role in
identifying patients and in barriers that may prevent them from ordering
BRCA genetic testing. Indicating that the majority of patients feel
comfortable with identifying patients that may be at an increased risk of
carrying a BRCA mutation and that perceived barriers to BRCA genetic
testing include the cost of testing and the fear of insurance discrimination.
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While our sample of Ob/Gyns reached across various hospital systems
in the Houston area, the overall sample size was small (n=83). Due to the
small sample size, there was not an adequate amount of respondents that fell
into each subspecialty. In this way the study was limited in terms of the
ability for further stratification and analysis by specialty. While this study’s
population is representative of the greater Houston area, one may not be able
to generalize these results to other areas of the country. Furthermore, all of
the factors measured in this study were based on the self-reporting of our
respondents, and may not accurately reflect true practice behaviors. Another
possible limitation is the presence of selection bias that may have resulted
due to the voluntary and thus self-selection of the study sample from our
target population. It is possible that the physicians who responded and are
part of our study sample may have a heightened interest in HBOC. If this
were the case, then the findings reported in this study may be skewed
towards those physicians who feel that identifying at risk patients is
important, those that may utilize testing more often, and those that may have
a higher amount of knowledge than their peers who chose not to complete
our survey. It is quite possible that results would actually be less favorable
in an unbiased sample. Another limitation of this study is that two formats of
the survey that were distributed. While some questions clearly stated to
85

choose only one answer, some participants with hard copy versions of the
survey chose more than one answer. Moreover, participants with the hard
copy version were free to go back to previous questions to change their
answers or write in answers. The online version prevented participants from
going back to previously answered questions and allowed limited areas for
write in answers. Finally, the survey distributed was not a validated survey,
as it was created specifically for this study.

Final Conclusions and Future Studies:
This study shows that the majority of Ob/Gyns feel that it is their role
to identify patients that may be at an increased risk of having a BRCA
mutation. Overall, reported comfort in identifying patients that may be at
and increased risk of having a BRCA mutation is high. Most Ob/Gyns would
agree that they are comfortable or very comfortable with this task.
Furthermore, most Ob/Gyns report that they would discuss HBOC and order
BRCA testing themselves once they have identified patients that may be at an
increased risk. However, only about a quarter of participants indicated that
they order BRCA genetic testing one to two times per month, or more.
Finally, this study demonstrates that the overall knowledge of HBOC and
BRCA testing is poor. Thus, this study points out the need for more
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education regarding HBOC, molecular BRCA testing, and strategies for
identifying patients that may be at risk for having a mutation in a BRCA
gene. Furthermore, it emphasizes the importance of raising awareness to
current practice guidelines and recommendations that can assist
obstetricians and gynecologist to better identify and manage patients that
may be at an increased risk of having HBOC, which could have otherwise
been overlooked.
Future directions of this study are to replicate the study across a larger
population of Ob/ Gyns to capture the attitudes, utilization, and knowledge
across a more diverse population. An education module with pre and post
testing could also be implemented to capture the significance of education
about HBOC and BRCA testing. Furthermore, another study to examine how
physicians are identifying patients that are at an increased risk may help
explain the reported level of comfort in identifying patients at an increased
risk of having a BRCA mutation that was seen in this study. Another
direction that could be taken is to adapt the survey questions created here to
analyze other physician’s knowledge about different hereditary cancers or
genetic conditions. Results of a survey like this could prove beneficial in
demonstrating the need for more genetics training, with the ultimate goal of
providing better patient care.
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APPENDIX A
Part I.
1.

What is your gender?
 Male
 Female

2.

How many years has it been since the completion of your primary residency?
_______________

3.

Are you board certified in Obstetrics and Gynecolgoy?
 Yes
 No

4.

Are you boarded in any sub-specialty?
 No
 Yes, please indicate which one(s) below:
i. Gynecologic Oncology
ii. Maternal Fetal Medicine
iii. Reproductive Endocrinology
iv. Urogynecology
v. Other: _____________

5.

Which of the following best describes your area of practice?
 General Obstetrics and Gynecology
 Gynecology only
 Obstetrics only
 Gynecologic oncology
 Maternal fetal medicine
 Reproductive endocrinology
 Urogynecology
 Other _________

6.

What is your primary practice setting? Choose all that apply.
 Private Practice- please indicate the number of Ob/Gyns in your group _______
 Academic Institution/University Medical Center
 Other ______________

7.

On average, how many patients do you see in the outpatient setting per week?
 <50
 51-100
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 101-150
 151-200
 >200

Part II.
1.

How comfortable do you feel identifying patients who are at an increased risk of carrying a
BRCA mutation?

Very Uncomfortable

2.

3.


Uncomfortable


Uncertain


Comfortable


Very Comfortable

Please indicate your answer choice by marking the appropriate column below:
Yes
That it is one of your practice responsibilities to identify patients who
may carry a mutation in BRCA1/2?
That your management of a patient would change if you knew she
carried a mutation in BRCA1/2?

No

Who do you feel has the primary responsibility of identifying patients who may be at an
increased risk of carrying a mutation in BRCA1/2?
 Obstetrician/ Gynecologist
 General Practitioner/ Primary Care Physician
 Radiologist
 Oncologist
 Other_____________________

4.

What barriers do you feel prevent you from ordering genetic testing of the BRCA genes?
Chose all that apply.
 Cost of the testing
 The possibility of insurance discrimination if patient is found to be a carrier
 Lack of patient interest/ uptake
 Time constraints in my clinic
 Lack of knowledge regarding which patients are eligible for testing
 I do not feel that I have any patients who are at an increased risk of having a BRCA
mutation
 I do not feel that it is relevant/ important to the care of my patients
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 Other _____________

Part III.
1.

Please indicate you answer choice by marking the appropriate column below:

On average, how many times each
month do you…

Neve

Rarely

Sometime

Often

On a

r

(<1

s

(3-4

regular

(1-2

times/mo)

basis

time/mo)

times/mo)

(≥5
times/mo)

See a patient that you suspect has an
increased risk for HBOC?
Receive questions from patients about
the heredity of breast cancer?
Receive questions from patients about
BRCA1/2 testing?
Initiate a conversation regarding
genetic testing for BRCA1/2 with your
patients?
Order genetic testing for BRCA1/2?
Refer a patient to a genetic counselor,
or other specialist, in order to discuss
genetic testing for BRCA1/2?

2.

If you identify a patient who you believe is at risk for carrying a mutation in BRCA1/2, what
would you do?
 Discuss hereditary breast and ovarian cancer and order the testing yourself
 Refer the patient to their primary care physician for testing
 Refer the patient to a genetic counselor for risk assessment and possible testing
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 Refer the patient to another specialist. Please specify which type of specialist:
_____________
 Nothing, because you do not feel that it would change your management of the
patient
1. Which of the following patients would you consider at an increased risk for
having a mutation in BRCA1 or BRCA2?
A patient who was diagnosed with breast cancer at 45 years but has no other family
history of breast cancer?
A patient whose mother was diagnosed with breast cancer at 60 years and whose
maternal grandmother was diagnosed with breast cancer at the age of 70 years?
A patient who was diagnosed with ovarian cancer at the age of 55 years?

Yes

No

 Other _______________

Part IV.

1-2. Please indicate your answer choice by marking the appropriate column below:
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A patient who is Ashkenazi Jewish and was diagnosed with breast cancer at the age
of 60 years?
A patient whose brother was diagnosed with breast cancer?
A patient whose paternal grandmother was diagnosed with breast cancer at the age
of 50 and whose paternal aunt was diagnosed with breast cancer at 49 years old?
A patient whose paternal cousin was diagnosed with endometrial cancer at 45 and
whose paternal aunt was diagnosed with colon cancer at 51?
A patient who has a family member with breast cancer, regardless of age.

2. Which of the following cancers are associated with BRCA mutations?

Yes

No

Breast cancer
Colon cancer
High grade serous or endometrioid ovarian cancer
Mucinous ovarian cancer
Prostate cancer
Uterine cancer
Fallopian tube cancer

3.

What is the lifetime risk for developing breast cancer for a woman who has a known BRCA
mutation?
 Up to 22%
 Up to 44%
 Up to 88%
 Virtually 100%
 I do not know

4.

What is the lifetime risk for
developing ovarian cancer for a woman who has a known BRCA mutation?
 Up to 22%
 Up to 44%
 Up to 88%
 Virtually 100%
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 I do not know

5.

What is the chance of a woman having a mutation in BRCA1/2 if she has a first degree
relative with a known BRCA mutation?
 0%
 25%
 50%
 100%
 This is dependent upon whether it is a maternal or paternal relative
 I do not know

6.

A woman can inherit a mutation in BRCA1/2:
 From her mother only
 From her father only
 From either her mother or her father
 These mutations are not typically inherited, it is most likely that the mutation
started in the affected individual
 I do not know

7.

What testing would you order for an Ashkenazi Jewish patient with a known familial
mutation in BRCA1/2?
 Comprehensive BRAC Analysis
 Multisite BRAC Analysis
 Single Site BRAC Analysis
 BRAC Analysis Large Rearrangement Testing (BART)
 I do not know

Please provide us with any comments regarding this survey, identifying patients at risk for
hereditary breast and ovarian cancer (HBOC) or BRCA testing:
_________________________________________________________________________________________
_________________________________________________________________________________________
_________________________________________________________________________________________

_________________________________________________________________________________________
_________________________________________________________________________________________
_______________
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APPENDIX B
Research study (Survey) Regarding Obstetricians and Gynecologists knowledge, attitudes toward, and
utilization of BRCA testing
You are invited to take part in a research project called, “Knowledge, attitudes toward, and utilization of
BRCA testing,” conducted by Salma Nassef, of the University of Texas Health Science Center. For this
research project, she will be called the Principal Investigator or PI.
The purpose of this research study is to assess obstetricians and gynecologists’ medical background,
experience, and opinions regarding the utilization of BRCA testing for their patient population. This
study is composed of multiple-choice questions, which we hope will allow us to better understand current
practice regarding this topic. Space is available for additional comments should you find this necessary.
There are no other alternative ways to participate in this study without filling out the survey below. There
are no known risks for your participation in this study.
Completion of this anonymous survey is voluntary and for research purposes only. It should take less
than 15 minutes to complete this survey. All responses are completely confidential, and you will not be
personally identified in any reports or publications of this study. Data will be summarized and presented
as part of a thesis project at The University of Texas Graduate School of Biomedical Sciences at Houston.
By completing and submitting the questionnaire, you are implying consent to have your answers used
and shared among collaborators for this study. There is no financial compensation for taking this survey.
Although the results of this study will be useful for doctors and other health professionals, there may be
no direct benefit to you for participating in this study. You can refuse to answer or skip any questions or
stop taking the survey at any time. Refusing to take part or stopping at any point during the survey will
involve no penalty. If you decide to participate in the study, it is very important that you answer the
questions as honestly as you can.
If you have any questions or concerns, please contact Salma Nassef or Cathy Sullivan, MS, CGC at 713500-6381. Thank you very much for your input regarding this important issue.
Sincerely,
Salma Nassef
Genetic Counseling Student
UT Health Science Center at Houston
Graduate School of Biomedical Sciences
Principal Investigator
Cathy M. Sullivan, MS, CGC
Genetic Counselor/Clinical Instructor
UT Health Science Center at Houston
Department of Obstetrics, Gynecology and Reproductive Sciences
Committee Chair
Manju Monga, MD
Senior Faculty
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